AbbVie Becomes An Overnight Oncology Force With Pharmacyclics
This article was originally published in The Pink Sheet Daily
Executive Summary
The company outbid two rivals to win Pharmacyclics and its fast-growing cancer drug Imbruvica in an expensive acquisition that will cost AbbVie about $21 billion. But the fact that Pharmacyclics shares sales and profits on Imbruvica with J&J may leave some investors questioning the high premium.